CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
Public ClinicalTrials.gov record NCT04523142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-center, Open-label, Single-arm Clinical Trial to Assess the Long-term Safety and Tolerability of Topical CyclASol® for the Treatment of Dry Eye Disease in Subjects Who Completed the Clinical Trial CYS-004
Study identification
- NCT ID
- NCT04523142
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novaliq GmbH
- Industry
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Interventions
- CyclASol Ophthalmic Solution Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 3, 2021
- Primary completion
- Apr 29, 2022
- Completion
- May 22, 2022
- Last update posted
- Oct 15, 2023
2021 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CYS-005 Investigational Site | Los Angeles | California | 90013 | — |
| CYS-005 Investigational Site | Newport Beach | California | 92663 | — |
| CYS-005 Investigational Site | Carmel | Indiana | 46290 | — |
| CYS-005 Investigational Site | Louisville | Kentucky | 40206 | — |
| CYS-005 Investigational Site | Andover | Massachusetts | 01810 | — |
| CYS-005 Investigtional Site | Raynham | Massachusetts | 02767 | — |
| CYS-005 Investigational Site | Henderson | Nevada | 89052 | — |
| CYS-005 Investigational Site | Raleigh | North Carolina | 27603 | — |
| CYS-005 Investigational Site | Shelby | North Carolina | 28150 | — |
| CYS-005 Investigational Site | Fargo | North Dakota | 58103 | — |
| CYS-005 Investigational Site | Cranberry Township | Pennsylvania | 16066 | — |
| CYS-005 Investigational Site | Memphis | Tennessee | 38119 | — |
| CYS-005 Investigational Site | Layton | Utah | 84041 | — |
| CYS-005 Investigational Site | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04523142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2023 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04523142 live on ClinicalTrials.gov.